The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
- 17 November 2014
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 15 (1), 81-100
- https://doi.org/10.1586/14737167.2015.982100
Abstract
Cetuximab (Erbitux) and panitumumab (Vectibix) are monoclonal antibodies to the EGFR. They are used as monotherapy or in combination with cytotoxic chemotherapy and increase both progression-free survival and overall survival in patients with wild-type RAS metastatic colorectal cancer. The most common side effects of therapy are dermatological, including skin (acneiform) rash, pruritus and hair changes. Despite their clinical activity, cost-effectiveness of the two drugs should be addressed in a discussion of their usage in everyday care. This study provides an up-to-date review of the clinical efficacy and cost-effectiveness of anti-EGFR inhibitors.Keywords
This publication has 79 references indexed in Scilit:
- CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).Journal of Clinical Oncology, 2014
- Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practiceCancer Treatment Reviews, 2012
- Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal CancerClinical Colorectal Cancer, 2011
- Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines CureJournal of Clinical Oncology, 2007
- Epidemiology and Management of Liver Metastases From Colorectal CancerAnnals of Surgery, 2006
- Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current EvidenceJournal of Clinical Oncology, 2005
- Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.Journal of Clinical Oncology, 1997
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1992